HIV Positive Clinical Trial
— PREZENTOfficial title:
A Phase IV 48 Week, Open Label, Pilot Study of Darunavir Boosted by Cobicistat in Combination With Rilpivirine to Treat HIV+ Naïve Subjects (PREZENT)
Current HIV treatment guidelines recommend the use of triple-drug therapy (two nucleoside reverse transcriptase inhibitors and either a protease inhibitor, non-nucleoside reverse transcriptase inhibitor, or an integrase inhibitor) for the treatment of antiretroviral (ARV)-naïve patients. With the introduction of highly active antiretroviral therapy (HAART), patients with HIV are living much longer. With the increasing lifespan of persons with HIV, long-term complications from therapy as well as the occurrence of co-morbidities with aging have prompted HCPs to re-think the current treatment paradigm and consider novel combinations of ARVs. All of the currently approved HIV antiretrovirals have been implicated in causing long-term toxicities; however the greatest body of evidence for long-term metabolic effects has implicated the nucleoside reverse transcriptase (NRTI) class. By utilizing a non-NRTI treatment regimen, it is hypothesized that many of these long-term metabolic effects (renal toxicity, bone loss, body fat changes) can be delayed or avoided altogether. The clinical data on novel combinations is currently limited but rapidly growing and has included several combinations that have utilized darunavir. This study will be the first of its kind using the unique combination of darunavir/cobicistat and rilpivirine. Currently, this drug combination is not a recommended option for first time treatment of HIV
Status | Not yet recruiting |
Enrollment | 30 |
Est. completion date | December 2016 |
Est. primary completion date | September 2016 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: 1. HIV-1 RNA = 5000 copies/mL by PCR 2. = 18 years of age 3. Cognitive ability to understand and provide written informed consent and willingness to participate in and comply with the study protocol 4. Less than 7 days of prior ART with any licensed or investigational compound 5. Patient does not currently have or has not been treated for an active opportunistic infection (OI) consistent with CDC definition (Appendix C) within 30 days of screening 6. Vital signs, physical examination and laboratory results do not exhibit evidence of acute illness 7. A female is eligible to enter and participate in this study if she is of non child bearing potential or child bearing potential, has a negative serum pregnancy test at screen. Exclusion Criteria 1. Patient with active AIDS-defining opportunistic infection or disease according to the 1993 CDC AIDS surveillance definition (Clinical Category C) in the 30 days prior to baseline and that, in the opinion of the investigator, would preclude the patient from participating in the study (See Appendix C). 2. Patient has none of the following darunavir-associated RAMs: V11I, V32I, L33F, I47V, I50V, I54L, I54M, T74P, L76V, I84V, L89V 3. Having documented genotypic evidence of NNRTI resistance at screening or from historical data available in the source documents, i.e. at least one of the NNRTI rams from the following list; K101E, K101P, E138A, E138G, E138K, E138R, E138Q, , V179L, Y181C, Y181I, Y181V, Y188L, H221Y, F227C, M230I, M230L, or the combination of the K103N and L100I. 4. History of active substance abuse, excluding cannabis, or psychiatric illness that, in the opinion of the investigator, would preclude compliance with protocol, dosing schedule and assessments. 5. Patient is either pregnant at time of screening evaluation or breast-feeding. 6. Patient, in the opinion of the investigator, is unlikely to be able to complete the 48-week dosing period and protocol evaluations and assessments or adhere to the study drug regimen. 7. Patient suffers from a serious medical condition, such as diabetes, congestive heart failure, cardiomyopathy or other cardiac dysfunction, which in the opinion of the investigator would compromise the safety of the patient 8. Patient has malabsorption syndrome or other gastrointestinal dysfunction, which may interfere with drug absorption or render the patient unable to take oral medication. 9. Patient is undergoing interferon therapy for HCV or anticipates undergoing therapy during the course of this trial 10. HBV co-infection 11. Patient has any of the following laboratory results within 30 days prior to the first dose of study medication: - Hemoglobin concentration < 8.0 g/dL - Absolute neutrophil count < 750 cells/mm3 - Platelet count <50,000 cells/ mm3 - Aminotransferase (AST, ALT) >3 times ULN - Serum creatinine >1.5 times the Upper Limits of Normal (ULN) 12. Patients with severe hepatic impairment 13. Patient has required treatment with radiation therapy or cytotoxic chemotherapeutic agents within 4 weeks prior to entry, or has an anticipated need for these agents within the study period. |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Therapeutic Concepts, P.A. | Houston | Texas |
United States | Therapeutic Concepts, PA | Houston | Texas |
Lead Sponsor | Collaborator |
---|---|
Therapeutic Concepts | Janssen Scientific Affairs, LLC |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of patients with plasma HIV-1 RNA <50 copies/mL | up to weeks 48 | Yes | |
Secondary | Proportion of patients with plasma HIV-1 RNA <400 copies/mL at each time point evaluated | At week 4, week 12, week 24, week 36, week 48 | Yes | |
Secondary | Number of weeks until HIV RNA <400 copies/mL and <50 copies/mL, respectively | At week 4, week 12, week 24 | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00639145 -
Elizabeth Glaser Pediatric AIDS Foundation Maternal Events and Pregnancy Outcomes (MEP Project)A Multi-site Protocol
|
||
Completed |
NCT01152684 -
Complementary & Alternative Medicine Use in HIV+ Latinos in the US-Mexico Border
|
||
Completed |
NCT01957748 -
CCTG 594: Engagement and Retention in Care for HIV+
|
N/A | |
Completed |
NCT01818258 -
IMPAACT P1092: Steady State PK in Malnourished HIV Infected Children
|
Phase 4 | |
Withdrawn |
NCT03660722 -
Bone, Inflammation, Gut and Renal Biomarkers in Antiretroviral Naïve HIV-1 Positive Subjects
|
N/A | |
Completed |
NCT01793467 -
Transplantation and the Use of Raltegravir in HIV-Infected Patients
|
N/A | |
Completed |
NCT02938377 -
Alcohol Research Consortium in HIV-Intervention Research Arm
|
Phase 4 | |
Completed |
NCT01898754 -
Oligonucleotide Ligation Assay (OLA) Resistance Study
|
N/A | |
Active, not recruiting |
NCT01365065 -
Safety and Effect on HIV Transcription of Vorinostat in Patients Receiving Suppressive Combination Anti-retroviral Therapy
|
Phase 2 | |
Completed |
NCT00106795 -
Relationship Between Fatigue and Mitochondrial Damage in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT01154543 -
Safety and Efficacy of Famciclovir in HIV1 Positive Adults With Recurrent Genital Herpes
|
N/A | |
Completed |
NCT01154556 -
RETRIeVE: ReversE TranscRiptase Inhibitor hiV Practice
|
N/A | |
Completed |
NCT00857350 -
The Prevalence of HIV Drug Resistance and Transmission Risk in Opioid Agonist Treatment
|
N/A | |
Recruiting |
NCT01875588 -
Thinking and Memory Problems in People With HIV
|
||
Completed |
NCT01941121 -
CCTG 593: Testing and Linkage to Care
|
N/A | |
Terminated |
NCT01904201 -
Evaluation of a Blood Test to Measure Immune Function in HIV Positive People Compared With HIV Negative People
|
N/A | |
Enrolling by invitation |
NCT00941889 -
The Effect of HPV Vaccination on Recurrence Rates in HIV Patients With Condylomata
|
N/A | |
Completed |
NCT03531749 -
Antioxidant in Patients HIV+ Supplemented With Microencapsulated of Red Pomegranate
|
N/A | |
Completed |
NCT02935296 -
Integrated Treatment and Prevention for People Who Inject Drugs
|
Phase 3 | |
Completed |
NCT01536912 -
Medical Marijuana Use in HIV+ Patients: Probability Survey
|
N/A |